Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

exercise or start new diets. It stands to reason that some of these resolutions might also lead to increased demand for weight-loss prescriptions such as GLP-1 drugs. If the logic is even half ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

It turned out she was right. Dr Cecil later learned her new non-profit insurance plan could not afford to cover the cost of the drugs. She gradually gained back most of the weight she lost. The latest ...

Dr Cecil later learned her new non-profit insurance plan could not afford to cover the cost of the drugs. She gradually gained back most of the weight she lost. The latest class of weight-loss ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that weight loss drugs like Ozempic and Wegovy can serve another purpose for ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this crowded field comes a new player ... approval in 2022; the company filed ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...